Comparative Pharmacology
Head-to-head clinical analysis: HEXADROL versus HI COR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXADROL versus HI COR.
HEXADROL vs HI-COR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to regulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin and leukotriene synthesis.
Adult: 0.75-9 mg/day orally in divided doses every 6-12 hours; IV/IM: initial 0.5-9 mg/day in divided doses every 6-12 hours.
0.1-0.2 mg/kg intravenously once.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours; prolonged in hepatic impairment (up to 72 hours) due to reduced clearance.
Terminal elimination half-life is 2-4 hours. Clinical context: Short half-life requires frequent dosing for sustained effect; accumulation possible in renal impairment.
Primarily renal: ~65-80% as unchanged drug and metabolites via glomerular filtration, with tubular reabsorption; minor biliary/fecal (5-10%).
Renal excretion of unchanged drug and metabolites accounts for approximately 70-80% of elimination, with biliary/fecal excretion contributing 20-30%.
Category C
Category C
Corticosteroid
Corticosteroid